2,769,316 Shares of Bristol Myers Squibb Company $BMY Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,769,316 shares of the biopharmaceutical company’s stock, valued at approximately $172,805,000.

Several other institutional investors have also recently bought and sold shares of BMY. Aviance Capital Partners LLC lifted its holdings in shares of Bristol Myers Squibb by 5.3% in the third quarter. Aviance Capital Partners LLC now owns 33,792 shares of the biopharmaceutical company’s stock worth $2,109,000 after acquiring an additional 1,690 shares during the last quarter. SFE Investment Counsel grew its holdings in shares of Bristol Myers Squibb by 1.6% during the 3rd quarter. SFE Investment Counsel now owns 12,412 shares of the biopharmaceutical company’s stock valued at $775,000 after purchasing an additional 200 shares during the last quarter. Profund Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 68.6% during the 3rd quarter. Profund Advisors LLC now owns 46,019 shares of the biopharmaceutical company’s stock valued at $2,872,000 after purchasing an additional 18,717 shares during the last quarter. ProShare Advisors LLC increased its position in Bristol Myers Squibb by 1.5% during the 3rd quarter. ProShare Advisors LLC now owns 340,113 shares of the biopharmaceutical company’s stock worth $21,223,000 after purchasing an additional 4,916 shares in the last quarter. Finally, Vise Technologies Inc. increased its position in Bristol Myers Squibb by 4.7% during the 3rd quarter. Vise Technologies Inc. now owns 148,608 shares of the biopharmaceutical company’s stock worth $9,273,000 after purchasing an additional 6,695 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BMY. HSBC reissued a “hold” rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Citigroup reiterated a “neutral” rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Morgan Stanley lowered their price target on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a report on Friday. Cantor Fitzgerald dropped their price target on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday, October 8th. Finally, Roth Capital began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $65.46.

Bristol Myers Squibb Stock Up 1.7%

Shares of NYSE BMY opened at $62.46 on Friday. The company has a 50 day simple moving average of $62.80 and a 200 day simple moving average of $59.94. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1 year low of $45.20 and a 1 year high of $68.64. The firm has a market cap of $127.59 billion, a PE ratio of 13.85, a price-to-earnings-growth ratio of 0.33 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 62.78%. The firm had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same period in the previous year, the firm posted $1.63 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.40 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is 55.88%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.